HomeIndustriesHealthcareEli Lilly’s Chart Gets Another Boost from Obesity Drug

Eli Lilly’s Chart Gets Another Boost from Obesity Drug

From diabetes to heart disease, the obesity drug Zepbound has been shown to have positive effects for other health ailments. Now, the company has a trial pointing to reduced sleep apnea severity. The health care giant’s stock has bounced on every drug-pipeline update, so Ben Lichtenstein decided to focus on the technical patters on Chart of the Day: Eli Lilly (LLY)

17 Apr 2024

SHARE

ON AIR
education
6:00 am
Schwab 2026 Outlook
replay
education
12:00 am
Schwab 2026 Outlook
REPLAY
1:00 am
Market Overtime
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Market Overtime
REPLAY
4:30 am
Market Overtime
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
Market Overtime
REPLAY
ON AIR
education
6:00 am
Schwab 2026 Outlook
REPLAY
7:00 am
Market Overtime
REPLAY
education
8:00 am
Your First Trade
REPLAY
education
8:30 am
Your First Trade
REPLAY
9:00 am
Fast Market
REPLAY
10:00 am
Market Overtime
REPLAY
10:30 am
Market Overtime
REPLAY
11:00 am
Market Overtime
REPLAY
11:30 am
Market Overtime
REPLAY
education
12:00 pm
Schwab 2026 Outlook
REPLAY
1:00 pm
Market Overtime
REPLAY
education
2:00 pm
Your First Trade
REPLAY
education
2:30 pm
Your First Trade
REPLAY
3:00 pm
Fast Market
REPLAY
4:00 pm
Market Overtime
REPLAY
4:30 pm
Market Overtime
REPLAY
5:00 pm
Market Overtime
REPLAY
5:30 pm
Market Overtime
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Market Overtime
REPLAY
education
8:00 pm
Your First Trade
REPLAY
education
8:30 pm
Your First Trade
REPLAY
9:00 pm
Fast Market
REPLAY
10:00 pm
Market Overtime
REPLAY
10:30 pm
Market Overtime
REPLAY
11:00 pm
Market Overtime
REPLAY
11:30 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor